Operator
Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Dave Connolly, Investor Relations. Please go ahead.
David Connolly
Head of Investor Relations & Corporate Communications
Thank you, Daniel, and good afternoon, everyone, and welcome. This afternoon, we issued a press release with the Phase III top line results for our EMANATE trial. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website. Listed on Slide 3 are the speakers for today’s call. David Meeker, Chair, President and Chief Executive Officer, will walk through these data. And Dr. Alastair Garfield, our Chief Scientific Officer; and Hunter Smith, our CFO, are available to answer questions on this call as well.
Before we get started, I would like to remind everyone that these statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the risk factors in our Risk Factors
